DBV Technologies | DBVT - Ebitda

Stock Price
20.53
Daily Change
0.47 2.34%
Monthly
-0.82%
Yearly
321.56%
Q1 Forecast
19.99

DBV Technologies reported $-33.48M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Galectin Therapeutics USD -7.42M 819K Dec/2021
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Incyte USD 414.5M 92.42M Dec/2025
Insmed USD -314.19M 31.48M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
United Therapeutics USD 379.5M 83.4M Dec/2025